Search

Your search keyword '"Chapman, M John"' showing total 997 results
Start Over Author "Chapman, M John" Search Limiters Academic (Peer-Reviewed) Journals
997 results on '"Chapman, M John"'

4. Adverse effects of statin therapy: perception vs. the evidence – focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract

Author

Mach, François, Ray, Kausik K, Wiklund, Olov, Corsini, Alberto, Catapano, Alberico L, Bruckert, Eric, De Backer, Guy, Hegele, Robert A, Hovingh, G Kees, Jacobson, Terry A, Krauss, Ronald M, Laufs, Ulrich, Leiter, Lawrence A, März, Winfried, Nordestgaard, Børge G, Raal, Frederick J, Roden, Michael, Santos, Raul D, Stein, Evan A, Stroes, Erik S, Thompson, Paul D, Tokgözoğlu, Lale, Vladutiu, Georgirene D, Gencer, Baris, Stock, Jane K, Ginsberg, Henry N, and Chapman, M John

Subjects
Aging, Brain Disorders, Prevention, Patient Safety, Liver Disease, Clinical Trials and Supportive Activities, Digestive Diseases, Stroke, Clinical Research, Evaluation of treatments and therapeutic interventions, Aetiology, 2.1 Biological and endogenous factors, 6.1 Pharmaceuticals, Cataract, Cerebral Hemorrhage, Chemical and Drug Induced Liver Injury, Cognition Disorders, Glucose, Homeostasis, Humans, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Kidney Diseases, European Atherosclerosis Society Consensus Panel, Cardiorespiratory Medicine and Haematology, Clinical Sciences, Cardiovascular System & Hematology
Abstract

AimsTo objectively appraise evidence for possible adverse effects of long-term statin therapy on glucose homeostasis, cognitive, renal and hepatic function, and risk for haemorrhagic stroke or cataract.Methods and resultsA literature search covering 2000-2017 was performed. The Panel critically appraised the data and agreed by consensus on the categorization of reported adverse effects. Randomized controlled trials (RCTs) and genetic studies show that statin therapy is associated with a modest increase in the risk of new-onset diabetes mellitus (about one per thousand patient-years), generally defined by laboratory findings (glycated haemoglobin ≥6.5); this risk is significantly higher in the metabolic syndrome or prediabetes. Statin treatment does not adversely affect cognitive function, even at very low levels of low-density lipoprotein cholesterol and is not associated with clinically significant deterioration of renal function, or development of cataract. Transient increases in liver enzymes occur in 0.5-2% of patients taking statins but are not clinically relevant; idiosyncratic liver injury due to statins is very rare and causality difficult to prove. The evidence base does not support an increased risk of haemorrhagic stroke in individuals without cerebrovascular disease; a small increase in risk was suggested by the Stroke Prevention by Aggressive Reduction of Cholesterol Levels study in subjects with prior stroke but has not been confirmed in the substantive evidence base of RCTs, cohort studies and case-control studies.ConclusionLong-term statin treatment is remarkably safe with a low risk of clinically relevant adverse effects as defined above; statin-associated muscle symptoms were discussed in a previous Consensus Statement. Importantly, the established cardiovascular benefits of statin therapy far outweigh the risk of adverse effects.

Published
2018

5. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel

Author

Ference, Brian A, Ginsberg, Henry N, Graham, Ian, Ray, Kausik K, Packard, Chris J, Bruckert, Eric, Hegele, Robert A, Krauss, Ronald M, Raal, Frederick J, Schunkert, Heribert, Watts, Gerald F, Borén, Jan, Fazio, Sergio, Horton, Jay D, Masana, Luis, Nicholls, Stephen J, Nordestgaard, Børge G, van de Sluis, Bart, Taskinen, Marja-Riitta, Tokgözoğlu, Lale, Landmesser, Ulf, Laufs, Ulrich, Wiklund, Olov, Stock, Jane K, Chapman, M John, and Catapano, Alberico L

Subjects
Cardiovascular, Atherosclerosis, Clinical Trials and Supportive Activities, Clinical Research, 2.1 Biological and endogenous factors, Aetiology, Anticholesteremic Agents, Cholesterol, HDL, Cholesterol, LDL, Consensus, Epidemiologic Methods, Ezetimibe, Genetic Predisposition to Disease, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Hyperlipidemias, Lipoproteins, LDL, PCSK9 Inhibitors, Cardiovascular disease, Causality, Clinical trials, Low-density lipoprotein, Mendelian randomization, PCSK9, Recommendations, Statin, Cardiorespiratory Medicine and Haematology, Clinical Sciences, Cardiovascular System & Hematology
Abstract

AimsTo appraise the clinical and genetic evidence that low-density lipoproteins (LDLs) cause atherosclerotic cardiovascular disease (ASCVD).Methods and resultsWe assessed whether the association between LDL and ASCVD fulfils the criteria for causality by evaluating the totality of evidence from genetic studies, prospective epidemiologic cohort studies, Mendelian randomization studies, and randomized trials of LDL-lowering therapies. In clinical studies, plasma LDL burden is usually estimated by determination of plasma LDL cholesterol level (LDL-C). Rare genetic mutations that cause reduced LDL receptor function lead to markedly higher LDL-C and a dose-dependent increase in the risk of ASCVD, whereas rare variants leading to lower LDL-C are associated with a correspondingly lower risk of ASCVD. Separate meta-analyses of over 200 prospective cohort studies, Mendelian randomization studies, and randomized trials including more than 2 million participants with over 20 million person-years of follow-up and over 150 000 cardiovascular events demonstrate a remarkably consistent dose-dependent log-linear association between the absolute magnitude of exposure of the vasculature to LDL-C and the risk of ASCVD; and this effect appears to increase with increasing duration of exposure to LDL-C. Both the naturally randomized genetic studies and the randomized intervention trials consistently demonstrate that any mechanism of lowering plasma LDL particle concentration should reduce the risk of ASCVD events proportional to the absolute reduction in LDL-C and the cumulative duration of exposure to lower LDL-C, provided that the achieved reduction in LDL-C is concordant with the reduction in LDL particle number and that there are no competing deleterious off-target effects.ConclusionConsistent evidence from numerous and multiple different types of clinical and genetic studies unequivocally establishes that LDL causes ASCVD.

Published
2017

6. SAFEHEART risk-equation and cholesterol-year-score are powerful predictors of cardiovascular events in French patients with familial hypercholesterolemia

Author

Angoulvant, Denis, Beliard, Sophie, Boccara, Franck, Bruckert, Eric, Cariou, Bertrand, Carreau, Valérie, Carrie, Alain, Charriere, Sybil, Cottin, Yves, Filippo, Mathilde DI., Dulong, Sonia, Durlach, Vincent, Farnier, Michel, Ferrari, Emile, Ferrieres, Dorota, Ferrieres, Jean, Gallo, Antonio, Giral, Philippe, Gonbert, Sophie, Hankard, Regis, Inamo, Jocelyn, Kalmykova, Olga, Krempf, Michel, Moulin, Philippe, Paillard, François, Peretti, Noel, Perrin, Agnes, Pierre Rabes, Jean, Sultan, Ariane, Tounian, Patrick, Valero, René, Verges, Bruno, Yelnik, Cecile, Ziegler, Olivier, Vimont, Alexandre, Chapman, M. John, Carrié, Alain, and Béliard, Sophie

Published
2020
Full Text
View/download PDF

7. Quantifying atherogenic lipoproteins for lipid-lowering strategies: Consensus-based recommendations from EAS and EFLM

Author

Nordestgaard, Børge G., Langlois, Michel R., Langsted, Anne, Chapman, M. John, Aakre, Kristin M., Baum, Hannsjörg, Borén, Jan, Bruckert, Eric, Catapano, Alberico, Cobbaert, Christa, Collinson, Paul, Descamps, Olivier S., Duff, Christopher J., von Eckardstein, Arnold, Hammerer-Lercher, Angelika, Kamstrup, Pia R., Kolovou, Genovefa, Kronenberg, Florian, Mora, Samia, Pulkki, Kari, Remaley, Alan T., Rifai, Nader, Ros, Emilio, Stankovic, Sanja, Stavljenic-Rukavina, Ana, Sypniewska, Grazyna, Watts, Gerald F., Wiklund, Olov, and Laitinen, Päivi

Published
2020
Full Text
View/download PDF

8. Rare dyslipidaemias, from phenotype to genotype to management: a European Atherosclerosis Society task force consensus statement

Author

Hegele, Robert A, Borén, Jan, Ginsberg, Henry N, Arca, Marcello, Averna, Maurizio, Binder, Christoph J, Calabresi, Laura, Chapman, M John, Cuchel, Marina, von Eckardstein, Arnold, Frikke-Schmidt, Ruth, Gaudet, Daniel, Hovingh, G Kees, Kronenberg, Florian, Lütjohann, Dieter, Parhofer, Klaus G, Raal, Frederick J, Ray, Kausik K, Remaley, Alan T, Stock, Jane K, Stroes, Erik S, Tokgözoğlu, Lale, and Catapano, Alberico L

Published
2020
Full Text
View/download PDF

10. Statin-associated muscle symptoms: impact on statin therapy—European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management

Author

Stroes, Erik S, Thompson, Paul D, Corsini, Alberto, Vladutiu, Georgirene D, Raal, Frederick J, Ray, Kausik K, Roden, Michael, Stein, Evan, Tokgözoğlu, Lale, Nordestgaard, Børge G, Bruckert, Eric, De Backer, Guy, Krauss, Ronald M, Laufs, Ulrich, Santos, Raul D, Hegele, Robert A, Hovingh, G Kees, Leiter, Lawrence A, Mach, Francois, März, Winfried, Newman, Connie B, Wiklund, Olov, Jacobson, Terry A, Catapano, Alberico L, Chapman, M John, Ginsberg, Henry N, Stroes, Erik, John Chapman, M, de Backer, Guy, Kees Hovingh, G, and Leiter, Lawrence

Subjects
Clinical Research, Cardiovascular, Atherosclerosis, 2.1 Biological and endogenous factors, Aetiology, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Cholesterol Ester Transfer Proteins, Complementary Therapies, Consensus, Creatine Kinase, Diet, Genetic Predisposition to Disease, Humans, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Hypolipidemic Agents, Mitochondria, Muscle, Mitochondrial Diseases, Muscular Diseases, Proprotein Convertase 9, Proprotein Convertases, Risk Factors, Serine Endopeptidases, European Atherosclerosis Society Consensus Panel, Cholesterol, Consensus statement, Lipids, Mitochondrial, Muscle symptoms, Myalgia, Myopathy, Statin, Statin intolerance, Cardiorespiratory Medicine and Haematology, Clinical Sciences, Cardiovascular System & Hematology
Abstract

Statin-associated muscle symptoms (SAMS) are one of the principal reasons for statin non-adherence and/or discontinuation, contributing to adverse cardiovascular outcomes. This European Atherosclerosis Society (EAS) Consensus Panel overviews current understanding of the pathophysiology of statin-associated myopathy, and provides guidance for diagnosis and management of SAMS. Statin-associated myopathy, with significant elevation of serum creatine kinase (CK), is a rare but serious side effect of statins, affecting 1 per 1000 to 1 per 10 000 people on standard statin doses. Statin-associated muscle symptoms cover a broader range of clinical presentations, usually with normal or minimally elevated CK levels, with a prevalence of 7-29% in registries and observational studies. Preclinical studies show that statins decrease mitochondrial function, attenuate energy production, and alter muscle protein degradation, thereby providing a potential link between statins and muscle symptoms; controlled mechanistic and genetic studies in humans are necessary to further understanding. The Panel proposes to identify SAMS by symptoms typical of statin myalgia (i.e. muscle pain or aching) and their temporal association with discontinuation and response to repetitive statin re-challenge. In people with SAMS, the Panel recommends the use of a maximally tolerated statin dose combined with non-statin lipid-lowering therapies to attain recommended low-density lipoprotein cholesterol targets. The Panel recommends a structured work-up to identify individuals with clinically relevant SAMS generally to at least three different statins, so that they can be offered therapeutic regimens to satisfactorily address their cardiovascular risk. Further research into the underlying pathophysiological mechanisms may offer future therapeutic potential.

Published
2015

11. 2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk

Author

Mach, François, Baigent, Colin, Catapano, Alberico L., Koskinas, Konstantinos C., Casula, Manuela, Badimon, Lina, Chapman, M. John, De Backer, Guy G., Delgado, Victoria, Ference, Brian A., Graham, Ian M., Halliday, Alison, Landmesser, Ulf, Mihaylova, Borislava, Pedersen, Terje R., Riccardi, Gabriele, Richter, Dimitrios J., Sabatine, Marc S., Taskinen, Marja-Riitta, Tokgozoglu, Lale, Wiklund, Olov, Windecker, Stephan, Aboyans, Victor, Collet, Jean-Philippe, Dean, Veronica, Fitzsimons, Donna, Gale, Chris P., Grobbee, Diederick, Halvorsen, Sigrun, Hindricks, Gerhard, Iung, Bernard, Jüni, Peter, Katus, Hugo A., Leclercq, Christophe, Lettino, Maddalena, Lewis, Basil S., Merkely, Bela, Mueller, Christian, Petersen, Steffen, Petronio, Anna Sonia, Roffi, Marco, Shlyakhto, Evgeny, Simpson, Iain A., Sousa-Uva, Miguel, Touyz, Rhian M., Nibouche, Djamaleddine, Zelveian, Parounak H., Siostrzonek, Peter, Najafov, Ruslan, van de Borne, Philippe, Pojskic, Belma, Postadzhiyan, Arman, Kypris, Lambros, Špinar, Jindřich, Larsen, Mogens Lytken, Eldin, Hesham Salah, Viigimaa, Margus, Strandberg, Timo E., Ferrières, Jean, Agladze, Rusudan, Laufs, Ulrich, Rallidis, Loukianos, Bajnok, László, Gudjónsson, Thorbjörn, Maher, Vincent, Henkin, Yaakov, Gulizia, Michele Massimo, Mussagaliyeva, Aisulu, Bajraktari, Gani, Kerimkulova, Alina, Latkovskis, Gustavs, Hamoui, Omar, Slapikas, Rimvydas, Visser, Laurent, Dingli, Philip, Ivanov, Victoria, Boskovic, Aneta, Nazzi, Mbarek, Visseren, Frank, Mitevska, Irena, Retterstøl, Kjetil, Jankowski, Piotr, Fontes-Carvalho, Ricardo, Gaita, Dan, Ezhov, Marat, Foscoli, Marina, Giga, Vojislav, Pella, Daniel, Fras, Zlatko, Perez de Isla, Leopoldo, Hagström, Emil, Lehmann, Roger, Abid, Leila, Ozdogan, Oner, Mitchenko, Olena, and Patel, Riyaz S.

Published
2019
Full Text
View/download PDF

23. Patients With High Genome-Wide Polygenic Risk Scores for Coronary Artery Disease May Receive Greater Clinical Benefit From Alirocumab Treatment in the ODYSSEY OUTCOMES Trial

Author

Damask, Amy, Steg, P. Gabriel, Schwartz, Gregory G., Szarek, Michael, Hagström, Emil, Badimon, Lina, Chapman, M. John, Boileau, Catherine, Tsimikas, Sotirios, Ginsberg, Henry N., Banerjee, Poulabi, Manvelian, Garen, Pordy, Robert, Hess, Sibylle, Overton, John D., Lotta, Luca A., Yancopoulos, George D., Abecasis, Goncalo R., Baras, Aris, and Paulding, Charles

Published
2020
Full Text
View/download PDF

24. Structure of HDL: Particle Subclasses and Molecular Components

Author

Kontush, Anatol, Lindahl, Mats, Lhomme, Marie, Calabresi, Laura, Chapman, M. John, Davidson, W. Sean, Rosenthal, Walter, Editor-in-chief, Barrett, James E., Series editor, Flockerzi, Veit, Series editor, Frohman, Michael A., Series editor, Geppetti, Pierangelo, Series editor, Hofmann, Franz B., Series editor, Michel, Martin C., Series editor, Moore, Philip, Series editor, Page, Clive P., Series editor, Thorburn, Andrew M., Series editor, Wang, KeWei, Series editor, von Eckardstein, Arnold, editor, and Kardassis, Dimitris, editor

Published
2015
Full Text
View/download PDF

27. Defining severe familial hypercholesterolaemia and the implications for clinical management: a consensus statement from the International Atherosclerosis Society Severe Familial Hypercholesterolemia Panel

Author

Santos, Raul D, Gidding, Samuel S, Hegele, Robert A, Cuchel, Marina A, Barter, Philip J, Watts, Gerald F, Baum, Seth J, Catapano, Alberico L, Chapman, M John, Defesche, Joep C, Folco, Emanuela, Freiberger, Tomas, Genest, Jacques, Hovingh, G Kees, Harada-Shiba, Mariko, Humphries, Steve E, Jackson, Ann S, Mata, Pedro, Moriarty, Patrick M, Raal, Frederick J, Al-Rasadi, Khalid, Ray, Kausik K, Reiner, Zelijko, Sijbrands, Eric J G, and Yamashita, Shizuya

Published
2016
Full Text
View/download PDF

28. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias: The Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR)

Author

Catapano, Alberico L., Graham, Ian, De Backer, Guy, Wiklund, Olov, Chapman, M. John, Drexel, Heinz, Hoes, Arno W., Jennings, Catriona S., Landmesser, Ulf, Pedersen, Terje R., Reiner, Željko, Riccardi, Gabriele, Taskinen, Marja-Riita, Tokgozoglu, Lale, Verschuren, W.M. Monique, Vlachopoulos, Charalambos, Wood, David A., and Zamorano, Jose Luis

Published
2016
Full Text
View/download PDF

31. The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and management

Author

Hegele, Robert A, Ginsberg, Henry N, Chapman, M John, Nordestgaard, Børge G, Kuivenhoven, Jan Albert, Averna, Maurizio, Borén, Jan, Bruckert, Eric, Catapano, Alberico L, Descamps, Olivier S, Hovingh, G Kees, Humphries, Steve E, Kovanen, Petri T, Masana, Luis, Pajukanta, Päivi, Parhofer, Klaus G, Raal, Frederick J, Ray, Kausik K, Santos, Raul D, Stalenhoef, Anton F H, Stroes, Erik, Taskinen, Marja-Riitta, Tybjærg-Hansen, Anne, Watts, Gerald F, and Wiklund, Olov

Published
2014
Full Text
View/download PDF

34. High Intestinal Cholesterol Absorption Is Associated With Cardiovascular Disease and Risk Alleles in ABCG8 and ABO: Evidence From the LURIC and YFS Cohorts and From a Meta-Analysis

Author

Silbernagel, Günther, Chapman, M. John, Genser, Bernd, Kleber, Marcus E., Fauler, Günter, Scharnagl, Hubert, Grammer, Tanja B., Boehm, Bernhard O., Mäkelä, Kari-Matti, Kähönen, Mika, Carmena, Rafael, Rietzschel, Ernst R., Bruckert, Eric, Deanfield, John E., Miettinen, Tatu A., Raitakari, Olli T., Lehtimäki, Terho, and März, Winfried

Published
2013
Full Text
View/download PDF

38. Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment

Author

Wiegman, Albert, Gidding, Samuel S., Watts, Gerald F., Chapman, M. John, Ginsberg, Henry N., Cuchel, Marina, Ose, Leiv, Averna, Maurizio, Boileau, Catherine, Borén, Jan, Bruckert, Eric, Catapano, Alberico L., Defesche, Joep C., Descamps, Olivier S., Hegele, Robert A., Hovingh, G. Kees, Humphries, Steve E., Kovanen, Petri T., Kuivenhoven, Jan Albert, Masana, Luis, Nordestgaard, Børge G., Pajukanta, Päivi, Parhofer, Klaus G., Raal, Frederick J., Ray, Kausik K., Santos, Raul D., Stalenhoef, Anton F.H., Steinhagen- Thiessen, Elisabeth, Stroes, Erik S., Taskinen, Marja-Riitta, Tybjærg-Hansen, Anne, Wiklund, Olov, Averna, Maurizio, Boileau, Catherine, Borén, Jan, Bruckert, Eric, Catapano, Alberico L., Chapman, M. John, Cuchel, Marina, Defesche, Joep C., Descamps, Olivier S., Gidding, Samuel S., Ginsberg, Henry N., Hegele, Robert A., Hovingh, G. Kees, Humphries, Steve E., Kovanen, Petri T., Kuivenhoven, Jan Albert, Masana, Luis, Nordestgaard, Børge G., Ose, Leiv, Pajukanta, Päivi, Parhofer, Klaus G., Raal, Frederick J., Ray, Kausik K, Santos, Raul D., Stalenhoef, Anton F. H., Steinhagen-Thiessen, Elisabeth, Stroes, Erik S., Taskinen, Marja-Riitta, Tybjærg-Hansen, Anne, Watts, Gerald F., Wiegman, Albert, Wiklund, Olov, Gidding, Samuel S., Watts, Gerald F., Chapman, M. John, Ginsberg, Henry N., Cuchel, Marina, Ose, Leiv, Chapman, M. John, and Ginsberg, Henry N.

Published
2015
Full Text
View/download PDF

40. Lipoprotein(a): Pathophysiology, measurement, indication and treatment in cardiovascular disease. A consensus statement from the Nouvelle Société Francophone d’Athérosclérose (NSFA)

Author

Durlach, Vincent, primary, Bonnefont-Rousselot, Dominique, additional, Boccara, Franck, additional, Varret, Mathilde, additional, Di-Filippo Charcosset, Mathilde, additional, Cariou, Bertrand, additional, Valero, René, additional, Charriere, Sybil, additional, Farnier, Michel, additional, Morange, Pierre E., additional, Meilhac, Olivier, additional, Lambert, Gilles, additional, Moulin, Philippe, additional, Gillery, Philippe, additional, Beliard-Lasserre, Sophie, additional, Bruckert, Eric, additional, Carrié, Alain, additional, Ferrières, Jean, additional, Collet, Xavier, additional, Chapman, M. John, additional, and Anglés-Cano, Eduardo, additional

Published
2021
Full Text
View/download PDF

41. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias

Author

Catapano, Alberico L., Graham, Ian, De Backer, Guy, Wiklund, Olov, Chapman, M. John, Drexel, Heinz, Hoes, Arno W., Jennings, Catriona S., Landmesser, Ulf, Pedersen, Terje R., Reiner, Željko, Riccardi, Gabriele, Taskinen, Marja-Riita, Tokgozoglu, Lale, Monique Verschuren, W.M., Vlachopoulos, Charalambos, Wood, David A., Luis Zamorano, Jose, and Cooney, Marie-Therese

Published
2017
Full Text
View/download PDF

42. Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society

Author

Cuchel, Marina, Bruckert, Eric, Ginsberg, Henry N., Raal, Frederick J., Santos, Raul D., Hegele, Robert A., Kuivenhoven, Jan Albert, Nordestgaard, Børge G., Descamps, Olivier S., Steinhagen-Thiessen, Elisabeth, Tybjærg-Hansen, Anne, Watts, Gerald F., Averna, Maurizio, Boileau, Catherine, Borén, Jan, Catapano, Alberico L., Defesche, Joep C., Hovingh, G. Kees, Humphries, Steve E., Kovanen, Petri T., Masana, Luis, Pajukanta, Päivi, Parhofer, Klaus G., Ray, Kausik K., Stalenhoef, Anton F. H., Stroes, Erik, Taskinen, Marja-Riitta, Wiegman, Albert, Wiklund, Olov, Chapman, M. John, Cuchel, Marina, Bruckert, Eric, Chapman, M. John, Descamps, Olivier S., Ginsberg, Henry N., Hegele, Robert A., Kuivenhoven, Jan Albert, Nordestgaard, Børge G., Raal, Frederick J., Santos, Raul D., Steinhagen-Thiessen, Elisabeth, Tybjærg-Hansen, Anne, Watts, Gerald F., Chapman, M. John, Ginsberg, Henry N., Averna, Maurizio, Boileau, Catherine, Borén, Jan, Catapano, Alberico L., Defesche, Joep C., Hovingh, G. Kees, Humphries, Steve E., Kovanen, Petri T., Masana, Luis, Pajukanta, Päivi, Parhofer, Klaus G., Ray, Kausik K., Stalenhoef, Anton F. H., Stroes, Erik, Taskinen, Marja-Riitta, Wiegman, Albert, and Wiklund, Olov

Published
2014
Full Text
View/download PDF

46. Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies—a consensus statement from the European Atherosclerosis Society

Author

Ginsberg, Henry N, primary, Packard, Chris J, additional, Chapman, M John, additional, Borén, Jan, additional, Aguilar-Salinas, Carlos A, additional, Averna, Maurizio, additional, Ference, Brian A, additional, Gaudet, Daniel, additional, Hegele, Robert A, additional, Kersten, Sander, additional, Lewis, Gary F, additional, Lichtenstein, Alice H, additional, Moulin, Philippe, additional, Nordestgaard, Børge G, additional, Remaley, Alan T, additional, Staels, Bart, additional, Stroes, Erik S G, additional, Taskinen, Marja-Riitta, additional, Tokgözoğlu, Lale S, additional, Tybjaerg-Hansen, Anne, additional, Stock, Jane K, additional, and Catapano, Alberico L, additional

Published
2021
Full Text
View/download PDF

47. Adipocyte ATP-Binding Cassette G1 Promotes Triglyceride Storage, Fat Mass Growth, and Human Obesity

Author

Frisdal, Eric, Le Lay, Soazig, Hooton, Henri, Poupel, Lucie, Olivier, Maryline, Alili, Rohia, Plengpanich, Wanee, Villard, Elise F., Gilibert, Sophie, Lhomme, Marie, Superville, Alexandre, Miftah-Alkhair, Lobna, Chapman, M. John, Dallinga-Thie, Geesje M., Venteclef, Nicolas, Poitou, Christine, Tordjman, Joan, Lesnik, Philippe, Kontush, Anatol, Huby, Thierry, Dugail, Isabelle, Clement, Karine, Guerin, Maryse, and Le Goff, Wilfried

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results